Peritoneal carcinoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:07 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Peritoneal carcinoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Farletuzumab Ecteribulin vs. Chemotherapy for Women with Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://clinicaltrials.eu/trial/study-of-farletuzumab-ecteribulin-vs-chemotherapy-for-women-with-platinum-resistant-high-grade-serous-ovarian-primary-peritoneal-or-fallopian-tube-cancer/ Wed, 29 Apr 2026 14:30:09 +0000 https://clinicaltrials.eu/trial/study-of-farletuzumab-ecteribulin-vs-chemotherapy-for-women-with-platinum-resistant-high-grade-serous-ovarian-primary-peritoneal-or-fallopian-tube-cancer/ This clinical trial is focused on studying a type of cancer known as platinum-resistant high-grade serous ovarian cancer, which can also affect the primary peritoneal or fallopian tube areas. The study is testing a new treatment called farletuzumab ecteribulin, also known by its code name MORAb-202. This treatment is a special kind of medicine called an antibody-drug conjugate, which is designed to target cancer cells more precisely. The trial will compare this new treatment to other chemotherapy options chosen by the doctors involved in the study.

The purpose of the study is to see how well MORAb-202 works compared to the other chemotherapy treatments. Participants in the study will receive either the new treatment or one of the standard chemotherapy options, which may include drugs like Caelyx (containing doxorubicin hydrochloride), paclitaxel, or topotecan. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The study will follow participants over a period of time to monitor their response to the treatment and any side effects they may experience. The main goal is to determine the effectiveness of MORAb-202 in treating this type of cancer and to assess the safety of the treatment. Participants will be closely monitored by healthcare professionals throughout the study to ensure their well-being and to gather important information about the treatment’s impact on their cancer.

]]>